Gil represents a monumental step forward in the application of induced pluripotent stem cells in treating the complications of diabetes,” said Michael P. In 2019, more than 11 percent of adults ages 18 and older reported severe vision issues or blindness and more than 1.87 million adults were diagnosed with major cardiovascular disease. These complications cause major metabolic disturbances that damage the cardiovascular, visual, peripheral nerve and renal systems through harming small and large microvessels that feed these tissues. What’s more, diabetes-related complications have risen among both young adults ages 18 to 44 years of age and adults ages 45 to 64. Centers for Disease Control and Prevention, more than 37 million people in the United States have diabetes–more than 11 percent of the U.S. “Unlike the use of embryonic stem cells (ESCs), genetically engineered hiPSCs do not carry the ethical challenges ESCs possess that limit their possible usage, and hiPSCs are being increasingly recognized as a viable alternative in study design and application as a cell therapy for human disorders,” Gil said.Īccording to the U.S. They hypothesized hiPSC-derived vascular reparative cells may serve as a source of endothelial precursors that will display in vivo vessel reparative properties in these diabetic subjects. Upon injection into animal model s with type 2 diabetic murine (T2D) retinal dysfunction, results showed significant improvement in visual acuity and electroretinograms with restoration of vascular perfusion. In the multi-site, early phase study recently published in Science Advances, investigators genetically reprogrammed diabetic and non-diabetic peripheral blood cells into hiPSCs and matured the cells into special blood vessel reparative cells. The results provide a foundation for an early phase clinical trial.” Our results demonstrate the safe, efficient and robust derivation of hiPSC-derived specific mesoderm subset for use as a novel therapy to rescue ischemic tissues and repair blood vessels in individuals with vascular diseases. “In this study, we focused on the retinal vessel in type 2 diabetes. “Vascular diseases afflict hundreds of millions of people in the world,” said Chang-Hyun Gil, MS, PhD, a postdoctoral fellow in the Department of Surgery and co-first author of the study. These research strategies include identifying and using new methods to differentiate or mature human induced pluripotent stem cells (hiPSCs) into the specific mesoderm subset of cells that display vascular reparative properties. and to serve as a resource for sharing iPS cell lines and iPSC technology within the UPenn and the broader scientific community.INDIANAPOLIS-Researchers at Indiana University School of Medicine, in collaboration with the University of Alabama at Birmingham and five other institutions, are investigating novel regenerative medicine approaches to better manage vascular health complications from type 2 diabetes that could someday support blood vessel repair in the eye among diabetic patients with early retinal vascular dysfunction.to provide expertise and training to researchers in ES/iPS cell culture.to facilitate derivation of iPS cells from somatic cells.The Penn Institute for Regenerative Medicine (IRM), which has been at the forefront of stem cell research and translational medicine, established the iPSC Core in 2009 to promote this powerful technology on campus and surrounding institutions. iPSC technology has undoubtedly become a powerful research tool and holds great potential in regenerative medicine. Since then, there has been an explosion of studies on iPSC technology, including reprogramming from human cells as well as different cell types new vectors and delivery modalities for expression of the transcription factors small molecule replacement(s) for the reprogramming genes reprogramming using micro RNAs and derivation of different cell lineages from iPS cells. Yamanaka and colleagues first reported in August 2006 the generation of murine iPSCs from fibroblasts by expression of four transcription factors. The reprogramming of somatic cells to induced pluripotent stem cells (iPSC) has proven to be a major advance in stem cell research. Please contact the director at the image for more information. We are also prepared to accommodate any immediate requests for research related to COVID-19. We are however working remotely and are available to discuss any current and future projects with users. The Penn iPSC Core has temporarily suspended laboratory operations per university policy until further notice.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |